^
    CANCER:

    Small Intestinal Carcinoma

    MSI-H/dMMR
    Small Intestinal Carcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    Ann Oncol - 2 weeks - (New C3)
    NTRK3 fusion
    Small Intestinal Carcinoma
    entrectinib
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    gemcitabine + docetaxel
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Small Intestinal Carcinoma
    entrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Small Intestinal Carcinoma
    entrectinib
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    gemcitabine + albumin-bound paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    LV5FU2
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Small Intestinal Carcinoma
    nivolumab
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Small Intestinal Carcinoma
    pembrolizumab + ipilimumab
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Small Intestinal Carcinoma
    nivolumab + ipilimumab
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    FOLFOX
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    CAPOX
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    bevacizumab
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    FOLFIRI
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    albumin-bound paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    paclitaxel + gemcitabine
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    carboplatin + paclitaxel
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Small Intestinal Carcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Small Intestinal Carcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Small Intestinal Carcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    GTX
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    FOLFOXIRI
    Sensitive: A2 - Guideline
    No biomarker
    Small Intestinal Carcinoma
    mFOLFOX6
    Sensitive: A2 - Guideline
    MSI-L/dMMR
    Small Intestinal Carcinoma
    dostarlimab
    Sensitive: A2 - Guideline
    RET fusion
    Small Intestinal Carcinoma
    selpercatinib
    Sensitive: C1 - Off-label
    PTEN mutation + MSI-H/dMMR
    Small Intestinal Carcinoma
    PD1 inhibitor
    Resistant: C3 – Early Trials
    MSI-H/dMMR + TMB-L
    Small Intestinal Carcinoma
    PD1 inhibitor
    Resistant: C3 – Early Trials
    VEGFA overexpression
    Small Intestinal Carcinoma
    bevacizumab
    Sensitive: C3 – Early Trials
    MSI-H/dMMR + TMB-H + PD-L1 overexpression
    Small Intestinal Carcinoma
    nivolumab + ipilimumab
    Sensitive: C4 – Case Studies
    BRAF V600E + MSI-H
    Small Intestinal Carcinoma
    CAPOX + BEV
    Sensitive: C4 – Case Studies